Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACRRead more
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with LenvimaRead more
Medivir to present at the Stockholm Corporate Finance Life Science DayRead more
Quarterly report presentations
Medivir Corporate Governance documention.
Documentation from Medivir's Annual General Meetings.